-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqUSDISIN US14817C1071-
CASSAVA SCIENCES INCBörse Gettex System der Börse MünchenEURSymbol PX91
-
CASSAVA SCIENCES INCBörse Börse DüsseldorfEURSymbol PX91
-
CASSAVA SCIENCES INCBörse Börse StuttgartEURSymbol PX91
-
CASSAVA SCIENCES INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol PX91
-
CASSAVA SCIENCES INCBörse Quotrix System der Börse DüsseldorfEURSymbol PX91
-
Cassava SciencesBörse NasdaqISIN US14817C1071 WKN: A2PGL8USDSymbol SAVA
-
ISIN US14817C1071 WKN: A2PGL8USDSymbol SAVA
-
EURSymbol PX91
-
EURSymbol PX91
-
EURSymbol PX91
-
MXN
-
ISIN US14817C1071
WKN A2PGL8
Symbol SAVA
Währung
USD
Börse
Nasdaq Zeitzone: Europe/Berlin
Firmenname
Cassava Sciences, Inc
Marktkapitalisierung
2.615.467.488 (+- 23%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
2.011.934.976 oder 3.219.000.000
Mitarbeiter
18 (+- 49%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
9 oder 26 Mitarbeiter
EBITDA -4.572.000
PEGRatio None
Buchwert 0.937
Zahlte zuletzt am 13.12.2012 eine Dividende von 5,25 . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 64,96 EUR -13,73%
Portrait der Cassava Sciences Aktie
Das Unternehmen Cassava Sciences, Inc aus USA beschäftigt 18 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Das Unternehmen Cassava Sciences, Inc ist nur in einem ETFs enthalten und somit ein unbekanntes oder von Investoren gemiedenes Unternehmen. Der ETF iShares MSCI USA Small Cap UCITS ETF gewichtet Cassava Sciences mit 0,08%.
Ein ETF investiert in Cassava Sciences, Inc
Dir gefallen die Informationen zu Cassava Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Cassava Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Cassava Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Cassava Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
104 News & Informationen zur Cassava Sciences Aktie
SHAREHOLDER ALERT: Robbins LLP Announces That Cassava Sciences, Inc. (SAVA) Is Being Sued For Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired
Cassava Sciences Stock Could Continue To Bleed (NASDAQ:SAVA)
The science behind Cassava's simufilam is being questioned, and so far the company's response has not been persuasive. Learn what this means for SAVA stock.
5 Takeaways From The Cassava Sciences & Citizen Petition Debacle (NASDAQ:SAVA)
The fallout from a citizen petition submitted to the FDA critiquing Cassava's Alzheimer's drug and asking for a trial halt continues. Read key takeaways here.
SAVA INVESTOR ALERT: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc.
NEW YORK, Aug. 31, 2021 /PRNewswire/ — Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit
The Law Offices Of Frank R. Cruz Announces The Filing Of A Securities Class Action On Behalf Of Cassava Sciences, Inc. (SAVA) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired
SAVA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Cassava Sciences, Inc.
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Western District of Texas
Why This Cassava Sciences Analyst Is Dropping Coverage
The selling in Cassava Sciences, Inc. (NASDAQ:SAVA) stock is continuing unabated amid the controversy surrounding its Alzheimer's study d…
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors With Losses To Secure Counsel Before Important Deadline – SAVA
WHY:Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cassava
Pre-market Movers: BBIG, AFRM, ATER, SPRT, KPLT, GSAT, ASTR…
The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.36 A.M. EDT)..
Cassava Sciences And Alzheimer's Disease: Raising Doubts (NASDAQ:SAVA)
Top executives are heavily invested in the drug both financially and emotionally. Cassava Sciences has not been able to extricate itself from the controversy yet.
SAVA ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
Robbins Geller Rudman & Dowd LLP announces that it filed a class action lawsuit charging Cassava Sciences, Inc. and certain of its executives with violations of the Securities Exchange Act of… | August 28, 2021
CLASS ACTION UPDATE for REKR, BZ and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
CLASS ACTION UPDATE for REKR, BZ and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
August 27,… | August 28, 2021
Cassava Sciences, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses…
Cassava Sciences Stock: A Bystander's Perspective (NASDAQ:SAVA)
The quality and integrity of SAVA's Alzheimer's drug is being questioned by a citizen petition to the FDA. Read a bystander's perspective of the situation here.
Cassava Sciences punches back, after Qaunterix took a swing by saying it didn’t interpret or prepare the disputed trial data
Quanterix Corp. took a swing at Cassava Sciences Inc. Friday, but then Cassava hit back, stressing that Quanterix was contracted to perform sample testing of…
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
Law Offices of Howard G. Smith continues its investigation on behalf of Cassava Sciences, Inc. investors concerning the Company’s possible violations of federal securities laws.
On August… | August 27, 2021
Mid-Afternoon Market Update: Crude Oil Rises 2%; Navios Maritime Acquisition Shares Climb On Merger News
Toward the end of trading Friday, the Dow traded up 0.63% to 35,436.38 while the NASDAQ rose 1.23% to 15,130.14. The S&P also rose, gaining 0….
Cassava Sciences Releases Statement Regarding Plasma P-tau Analysis From A Previously Disclosed Phase 2b Clinical Study In Alzheimer's Patients
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a
Why Cassava Sciences Stock Investors Are Pulling Back
The neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ:SAVA) hasnow lost half of its market capitalization as skelet…
Mid-Morning Market Update: Markets Open Higher; Big Lots Reports Downbeat Profit
Following the market opening Friday, the Dow traded up 0.30% to 35,320.11 while the NASDAQ rose 0.27% to 14,986.36. The S&P also rose, gaining 0.33% to …
Cassava's stock tumbles again, after Quanterix said it 'did not' prepare data charts presented by Cassava, that are under dispute
Quanterix Corp. undefined said that while it was previously engaged by Cassava Sciences Inc. undefined to perform sample testing, the digitized biomarker…
Specious Claims And Spurious Accusations Against Cassava Sciences (NASDAQ:SAVA)
The petition filed against Cassava Sciences is so misleading and wrong-headed it seems an intentional act of FUD and not a serious request.
After A 30% Fall Cassava Stock Is Likely To See Lower Levels
The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimer’s disease, has seen a large 31% decline in a single trading session on Aug 25. SAVA stock has had a volatile ride over the last year or so, and despite yesterday’s fall, the stock is…
Quanterix : Releases Statement
Quanterix Corporation , a company digitizing biomarker analysis to advance the science of precision health, today released the following statement in response to news reports related to Cassava… | August 27, 2021